Loading...
•
Mar 31, 2020
Corcept Therapeutics Q1 2020 Earnings Report
Announced first quarter 2020 financial results and provided a corporate update.
Key Takeaways
Corcept Therapeutics reported a strong first quarter with revenue of $93.2 million, a 44% increase from Q1 2019. GAAP diluted net income was $0.25 per share, and non-GAAP diluted net income was $0.34 per share. The company reaffirmed its 2020 revenue guidance of $355 — 375 million.
Revenue of $93.2 million, a 44 percent increase from first quarter 2019
GAAP diluted net income of $0.25 per share, compared to $0.15 per share in first quarter 2019
Non-GAAP diluted net income of $0.34 per share, compared to $0.20 per share in first quarter 2019
Cash and investments of $349.0 million, compared to $315.3 million in fourth quarter 2019
Forward Guidance
Corcept reaffirmed its 2020 revenue guidance of $355 — 375 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...